RecruitingNCT05648591
One-year iloperidone safety study in adolescents with schizophrenia or bipolarity type I
About this title
Read the official source — NCT05648591Medication studyAges 12–17United States
Understand this study
Who could participate?
Listed age limits: 12 years to 17 years.
What will I do during this study?
Adolescents with schizophrenia or bipolarity receive open-label iloperidone for up to 52 weeks. The registry entry describes a safety and tolerability study but does not give a dosing or visit schedule.
- Listed locations
- Dothan and 10 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: May 24, 2023
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 100
- Sponsor
- Vanda Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 12 Years to 17 Years
- Official registry ID
- NCT05648591
- Official title
Show the full official title
Open-label Safety Study of a 1-year 8 to 24 mg/Day Dose Regimen of Iloperidone (FANAPT®) in Adolescent Patients With Schizophrenia or Bipolar I Disorder
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Dothan · Little Rock · Denver
7 more locations
- Atlanta
- Decatur
- Kinston
- Cincinnati
- Garfield Heights
- Westlake
- Everett
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Vanda Pharmaceuticals.
Does this study involve medication?
Yes. The study involves medication, including Iloperidone.
Who can participate?
Listed age limits: 12 years to 17 years.
Is this study still recruiting?
The registry lists this study as recruiting.
